Eli Lilly Obesity Drug Surpasses 7,000 Prescriptions Within Four Weeks of Launch

Eli Lilly's new oral weight-loss drug, Foundayo, has established a market presence, recording 7,335 prescriptions within four weeks of its launch.

The drug received approval from the U.S. Food and Drug Administration (FDA) in April of this year and began shipments on April 1st. It started becoming available through pharmacies and online telemedicine services from April 6th, with nationwide distribution commencing on April 9th in the United States.

Foundayo enters the obesity treatment market, following competitor Novo Nordisk's Wegovy, and while initial demand growth has been somewhat slow, it is gradually expanding its competitive reach. RBC Capital Markets analyst Truong Huynh acknowledged that Foundayo's prescription numbers have not met expectations but noted a trend among investors to avoid getting bogged down by early indicators.